VIRIP (trifluoroacetate salt)

VIRIP is an HIV entry inhibitor (IC50 = 26 µM) and a peptide fragment of the serine protease inhibitor alpha-1 antitrypsin.1,2 It is produced by C-terminal cleavage of alpha-1 antitrypsin by matrix metalloproteinase-7 (MMP-7).2 VIRIP (100 µM) inhibits HIV-1 replication in isolated human peripheral blood mononuclear cells (PBMCs) and transmission by monocyte-derived dendritic cells to primary T cells.1 Plasma levels of VIRIP are increased in patients with HIV infection.2WARNING This product is not for human or veterinary use.

[1] JAN MÜNCH. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.[J]. Cell, 2007, 129 2: 263-275. DOI: 10.1016/j.cell.2007.02.042
[2] HOLGER B KRAMER. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection.[J]. PLoS Pathogens, 2010, 6 5: e1000893. DOI: 10.1371/journal.ppat.1000893